Johnson & Johnson
Johnson & Johnson Reports Strong Q1 2026 Results and Increases Dividend
Summary
Johnson & Johnson reported a 9.9% increase in first-quarter 2026 sales to $24.1 billion, with operational growth of 6.4% and adjusted operational growth of 5.3%. The company also announced a 3.1% increase in its quarterly dividend to $1.34 per share, marking the 64th consecutive year of dividend increases. Additionally, the company highlighted several regulatory approvals and product launches, including the FDA approval of TECNIS PureSee Intraocular Lens and the launch of VARIPULSE Pro in Europe.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement